These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11228817)

  • 1. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
    Li-McLeod J; Perfetto EM
    Manag Care Interface; 2001 Feb; 14(2):52-9. PubMed ID: 11228817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
    Urueta-Robledo J; Ariza H; Jardim JR; Caballero A; García-Calderón A; Amábile-Cuevas CF; Hernández-Oliva G; Vivar-Orozco R;
    Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective.
    Vicente-Herrero T; Burke TA; Laínez MJ
    Curr Med Res Opin; 2004 Nov; 20(11):1805-14. PubMed ID: 15537481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect cost of ischemic heart disease to employers.
    Guico-Pabia CJ; Murray JF; Teutsch SM; Wertheimer AI; Berger ML
    Am J Manag Care; 2001 Jan; 7(1):27-34. PubMed ID: 11209448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study].
    Rychlik R; Pfeil T; Daniel D; Pfeil B; Mast O; Thate-Waschke I; Lorenz J
    Dtsch Med Wochenschr; 2001 Mar; 126(13):353-9. PubMed ID: 11332229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
    Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
    Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
    Grossman R; Mukherjee J; Vaughan D; Eastwood C; Cook R; LaForge J; Lampron N
    Chest; 1998 Jan; 113(1):131-41. PubMed ID: 9440580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN; Friedman HS; Perfetto EM
    Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG; Barghout V; Kahler KH
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease.
    Ruiz-González A; Giménez A; Gómez-Arbonés X; Soler-González J; Sánchez V; Falguera M; Porcel JM
    Respirology; 2007 Jan; 12(1):117-21. PubMed ID: 17207036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of broad-spectrum antibiotic use for acute sinusitis, chronic bronchitis, and pneumonia in a managed care population.
    Coughlin CM; Nelson M; Merchant S; Gondek K
    Manag Care Interface; 2003 Jun; 16(6):34-40, 55. PubMed ID: 12841074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany].
    Weissflog D; Matthys H; Virchow JC
    Dtsch Med Wochenschr; 2001 Jul; 126(28-29):803-8. PubMed ID: 11499261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work.
    Li X; Gignac MA; Anis AH
    Med Care; 2006 Apr; 44(4):304-10. PubMed ID: 16565630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.
    Miravitlles M; Ros F; Cobos A; Kubin R; Tillotson G
    Int J Clin Pract; 2001 Sep; 55(7):437-41. PubMed ID: 11594251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment in work productivity and health-related quality of life in patients with IBS.
    Dean BB; Aguilar D; Barghout V; Kahler KH; Frech F; Groves D; Ofman JJ
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S17-26. PubMed ID: 15926760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
    Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
    Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.